Renoprotective effects of pentoxifylline in the PREDIAN trial

Research output: Contribution to journalShort SurveyOtherpeer-review

5 Citations (Scopus)


The PREDIAN trial investigated the renoprotective effects of pentoxifylline, in addition to renin-angiotensin system blockade, in patients with type 2 diabetes mellitus and chronic kidney disease. This promising approach resulted in a reduction in the rate of decline in estimated glomerular filtration rate and a significant decrease in albuminuria.

Original languageEnglish
Pages (from-to)547-548
Number of pages2
JournalNature Reviews Nephrology
Issue number10
Publication statusPublished - 1 Jan 2014
Externally publishedYes

Cite this